Se Young Choi1, Bumjin Lim2, Yoon Soo Kyung2, Yunlim Kim2, Bong Min Kim2, Byung Hee Jeon3, Jae Chan Park3, Young Woong Sohn3, Jae Hyuk Lee3, Ji-Hyun Uh3, Seongsoo Jang4, Choung-Soo Kim5. 1. Department of Urology, Chung-Ang University Hospital, Chung-Ang University College of Medicine, Seoul, Republic of Korea. 2. Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea. 3. Cytogen, Seoul, Republic of Korea. 4. Department of Laboratory Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea. 5. Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea cskim@amc.seoul.kr.
Abstract
AIM: To evaluate the clinical efficacy of a circulating tumor cell (CTC) test by comparison between healthy volunteers and patients with localized prostate cancer including those under active surveillance. MATERIALS AND METHODS: CTC counts in peripheral blood were compared between patients with prostate cancer (n=45) and healthy volunteers (n=17). CTCs were identified based on the expression of epithelial cell adhesion molecule (EpCAM) and counted using a SMART BIOPSY™ SYSTEM. RESULTS: The number of EpCAM+ cells was significantly higher in patients with cancer than in healthy volunteers. Among the low-risk patients (n=9), two had up-staging and six had up-grading. Among those up-staged, there was one case which was EpCAM+ Among those cases up-graded, three were EpCAM+ In those with stage T2 tumors, the presence of Gleason pattern 5 was positively correlated with EpCAM positivity (rho=0.59, p<0.001). CONCLUSION: CTC counts in localized prostate cancer were associated with Gleason pattern 5. Active treatment should be considered for patients with low-risk disease during active surveillance who are found to have EpCAM+ CTCs because of a risk of up-staging and up-grading. Copyright
AIM: To evaluate the clinical efficacy of a circulating tumor cell (CTC) test by comparison between healthy volunteers and patients with localized prostate cancer including those under active surveillance. MATERIALS AND METHODS: CTC counts in peripheral blood were compared between patients with prostate cancer (n=45) and healthy volunteers (n=17). CTCs were identified based on the expression of epithelial cell adhesion molecule (EpCAM) and counted using a SMART BIOPSY™ SYSTEM. RESULTS: The number of EpCAM+ cells was significantly higher in patients with cancer than in healthy volunteers. Among the low-risk patients (n=9), two had up-staging and six had up-grading. Among those up-staged, there was one case which was EpCAM+ Among those cases up-graded, three were EpCAM+ In those with stage T2 tumors, the presence of Gleason pattern 5 was positively correlated with EpCAM positivity (rho=0.59, p<0.001). CONCLUSION: CTC counts in localized prostate cancer were associated with Gleason pattern 5. Active treatment should be considered for patients with low-risk disease during active surveillance who are found to have EpCAM+ CTCs because of a risk of up-staging and up-grading. Copyright
Authors: Sabine Riethdorf; Herbert Fritsche; Volkmar Müller; Thomas Rau; Christian Schindlbeck; Brigitte Rack; Wolfgang Janni; Cornelia Coith; Katrin Beck; Fritz Jänicke; Summer Jackson; Terrie Gornet; Massimo Cristofanilli; Klaus Pantel Journal: Clin Cancer Res Date: 2007-02-01 Impact factor: 12.531
Authors: W Jeffrey Allard; Jeri Matera; M Craig Miller; Madeline Repollet; Mark C Connelly; Chandra Rao; Arjan G J Tibbe; Jonathan W Uhr; Leon W M M Terstappen Journal: Clin Cancer Res Date: 2004-10-15 Impact factor: 12.531
Authors: Giorgio I Russo; Simone Bier; Jörg Hennenlotter; Gunthild Beger; Lucretia Pavlenco; Jens van de Flierdt; Siegfried Hauch; Moritz Maas; Simon Walz; Steffen Rausch; Jens Bedke; Giuseppe Morgia; Arnulf Stenzl; Tilman Todenhöfer Journal: BJU Int Date: 2018-04-10 Impact factor: 5.588
Authors: Ruth Etzioni; Alex Tsodikov; Angela Mariotto; Aniko Szabo; Seth Falcon; Jake Wegelin; Dante DiTommaso; Kent Karnofski; Roman Gulati; David F Penson; Eric Feuer Journal: Cancer Causes Control Date: 2007-11-20 Impact factor: 2.506
Authors: Thomas A Stamey; Mitchell Caldwell; John E McNeal; Rosalie Nolley; Marci Hemenez; Joshua Downs Journal: J Urol Date: 2004-10 Impact factor: 7.450
Authors: Johann S de Bono; Howard I Scher; R Bruce Montgomery; Christopher Parker; M Craig Miller; Henk Tissing; Gerald V Doyle; Leon W W M Terstappen; Kenneth J Pienta; Derek Raghavan Journal: Clin Cancer Res Date: 2008-10-01 Impact factor: 12.531